Relmada Therapeutics (NASDAQ: RLMD) furnishes new corporate presentation

Rhea-AI Filing Summary

Relmada Therapeutics, Inc. filed a current report to note that it updated its corporate presentation on September 17, 2025. The updated presentation is provided as Exhibit 99.1 and is incorporated by reference into the Regulation FD disclosure section of the report.

The company states that this information, including Exhibit 99.1, is being furnished under Regulation FD and is not deemed filed for purposes of certain liability provisions of the federal securities laws. No financial results, transactions, or other operational changes are described in this excerpt beyond the availability of the new corporate presentation.

false 0001553643 0001553643 2025-09-17 2025-09-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 17, 2025

RELMADA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Nevada		001-39082		45-5401931
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

2222 Ponce de Leon Blvd., Floor 3 Coral Gables, FL		33134
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (786) 629-1376

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of exchange on which registered
Common stock, $0.001 par value per share		RLMD		The NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐  

Item 7.01 Regulation FD Disclosure.

On September 17, 2025, Relmada Therapeutics, Inc. (the “Company”) updated its corporate presentation, a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. 

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1*		Corporate Presentation dated September 17, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Furnished herewith.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 17, 2025	RELMADA THERAPEUTICS, INC.
	By:	/s/ Sergio Traversa
	Name:	Sergio Traversa
	Title:	Chief Executive Officer

2

FAQ

What did Relmada Therapeutics (RLMD) report in this 8-K filing?

Relmada Therapeutics reported that it updated its corporate presentation on September 17, 2025 and furnished the updated presentation as Exhibit 99.1 to the report.

What is included as Exhibit 99.1 in Relmada Therapeutics' 8-K?

Exhibit 99.1 is a Corporate Presentation dated September 17, 2025, which the company furnished in connection with its Regulation FD disclosure.

Is the updated Relmada Therapeutics corporate presentation considered filed with the SEC?

No. The company states that the information in Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed filed for purposes of Section 18 of the Exchange Act.

Which exchange lists Relmada Therapeutics common stock and under what symbol?

Relmada Therapeutics' common stock, with a par value of $0.001 per share, is listed on The NASDAQ Capital Market under the trading symbol RLMD.

Who signed this Relmada Therapeutics 8-K report?

The report was signed on behalf of Relmada Therapeutics, Inc. by Sergio Traversa, the company’s Chief Executive Officer, dated September 17, 2025.

Under which item of Form 8-K did Relmada Therapeutics furnish the corporate presentation?

The corporate presentation was furnished under Item 7.01, Regulation FD Disclosure, of the Form 8-K.